1 / 47

Pharmacology of Antidysrhythmic and Vasoactive Medications

A comprehensive guide to the pharmacology of various antidysrhythmic and vasoactive medications including lidocaine, procainamide, beta blockers, amiodarone, calcium channel antagonists, and other dysrhythmics/vasoactives.

rainwater
Download Presentation

Pharmacology of Antidysrhythmic and Vasoactive Medications

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Pharmacology of Antidysrhythmic and Vasoactive Medications dr shabeel pn

  2. Class I Antidysrhythmics • Lidocaine (Xylocaine) • Procainamide (Pronestyl) • Propafenone (Rythmol) • Flecainide (Tambocor)

  3. Lidocaine (Class Ib) • Binds fast sodium channels, inhibiting recovery after repolarization • Suppresses spontaneous depolarization of the ventricles during diastole • Acts on ischemic myocardium

  4. Lidocaine • Onset of action: 45-90 seconds • Indications: • Ventricular dysrhythmias and ectopy • Sinus maintenance after pulseless VT/VF • Second-line for hemodynamically stable VT

  5. Lidocaine • Dosing: • Load 1-1.5 mg/kg, max of 3 mg/kg • Infuse at 1-4 mg/min (maintenance usually 2 mg/min) • Adverse effects: • Above 9 mg/min, may cause CNS depression, seizures, respiratory depression

  6. Procainamide (Class Ia) • Prevents ectopic or reentrant dysrhythmias • Anticholinergic properties in large doses • Potentially pro-dysrhythmic • Prolonged QRS and QT intervals, PVCs, VT, VF, complete AV block • Beware hypotension secondary to peripheral vasodilation

  7. Procainamide • Onset: 5-10 min • Indications: • Recurrent ventricular dysrhythmias • stable VT & wide complex tachycardia • Pulseless VT/VF • Converting PSVT, a fib, a flutter

  8. Procainamide • Contraindications: • Torsades & all blocks except first degree • Myasthenia gravis (will increase weakness) • Dosing: • Load 20 mg/min up to 17 mg/kg then infuse at 1-4 mg/min to maintain suppression

  9. Class II Antidysrhythmics • BETA BLOCKERS • Treatment of hypertension • Decrease morbidity and mortality: • Acute MI (metoprolol and atenolol) • CHF (metoprolol and carvedilol)

  10. Beta Blockers • Cardioselective (specific for β1 receptors): • atenolol, esmolol, metoprolol • Useful with asthma, COPD, or diabetes • Cardioselectivity lost at high doses

  11. Labetalol (Normodyne) • Non-cardioselective β-blocker and selective α1-adrenergic blocker • The β-blocker effects exceed the α1-blocking effects at a 7:1 ratio if given IV • Decreases heart rate, contractility, cardiac output, cardiac work, and peripheral resistance

  12. Labetalol • Onset: 2-5 min; duration 2-4 hrs • Indications: • HTN in patients with myocardial ischemia • Minimally changes heart rate and cardiac output • Acute neurological emergencies • little effect on cerebral perfusion pressure or ICP

  13. Labetalol • Dosing: • IV bolus 20 mg, repeat 40-80 mg q10 min prn up to 300 mg • Infuse 0.5-2 mg/min to desired effect • Adverse effects: • orthostatic hypotension, heart failure, lethargy, increased liver enzymes

  14. Class III Antidysrhythmics • Amiodarone (Cordarone) • Dofetilide (Tidosyn) • Ibutilide (Corvert)

  15. Amiodarone • Inhibits sodium channels and β-adrenergics • Prolongs action potential duration & effective refractory period  delays repolarization • Impairs SA and AV nodal function and prolongs refractory period in accessory pathways

  16. Amiodarone • Indications: • Ventricular and supraventricular dysrhythmias • Recurrent VF and VT, atrial fib/flutter, and junctional & wide-complex tachycardias • Pulseless VT/VF and atrial dysrhythmias with LVEF<40%

  17. Amiodarone • Dosing: • Pulseless VT/VF: • Load 300 mg IV, repeat 150 mg IV • Other dysrhythmias: • Load 150 mg IV, then infuse 1 mg/min X 6 hours, then 0.5 mg/min thereafter • Adverse effects: • Hypotension, bradycardia, asystole, cardiac arrest, shock • Contains iodine – avoid if allergic to iodine or shellfish

  18. Class IV Antidysrhythmics: • Calcium Channel Antagonists • Diltiazem (Cardizem) • Verapamil (Verelan, Calan, Isoptin)

  19. Diltiazem 1) Interferes slow channel extracellular calcium influx in cardiac smooth muscle 2) Inhibits sodium influx through fast channels • Slows AV nodal conduction/prolongs refraction • Dilates coronary vasculature  decreases O2 consumption/ improves O2 delivery

  20. Diltiazem • Onset: 2-3 min IV; 15-60 min PO • Indications: • Rapid conversion of PSVT to NSR • Ventricular slowing in atrial fib/flutter • Do NOT use for wide-complex tachydysrhythmias suggesting an accessory bypass tract (i.e. WPW syndrome)

  21. Diltiazem • Dosing: • Load 0.25 mg/kg (max 20 mg) IV push over 2 min, repeat in 15 minutes with 0.35 mg/kg (max 25 mg) IV push over 2 minutes if patient not responsive • Infuse at 5 mg/hr (max 15 mg/hr) • Adverse effects: • Angina, bradycardia, asystole, CHF, AV block, bundle branch block, hypotension, peripheral edema

  22. Verapamil • Action & Adverse Effects similar to Diltiazem • Indications: • As in Diltiazem • Essential HTN • Avoid in WPW patients (may accelerate bypass tract conduction) • Dosing: • For PSVT: 5-10 mg IV push over 2 min

  23. Other Dysrhythmics/Vasoactives • Adenosine • Digoxin • Atropine • Dobutamine • Vasopressin

  24. Adenosine (Adenocard) • Transient AV nodal block • breaks re-entrant circuit of AV nodal atrial tachydysrhythmia • No effect on non-AV nodal re-entrant SVTs or anterograde conduction over accessory pathways in WPW • As rapid IV bolus - slows cardiac conduction and restores sinus rhythm • Infused - acts as a potent vasodilator.

  25. Adenosine • Onset: 20-30 seconds; Half-life <10 seconds • Indications: Emergency treatment of SVT • Distinguish Afib/AFlutter from other tachydysrhythmias • Contraindications: • 2nd and 3rd degree AV block or sick sinus syndrome

  26. Adenosine • Dosing: • 6 mg rapid IV bolus, most proximal port then 12 mg rapid IV bolus every 1-2 min prn x2 doses • Follow bolus immediately with 10-20 cc flush • Adverse effects (usu.minor and well-tolerated) • Dyspnea, syncope, vertigo, metallic taste, flushing, chest pain, bradycardia, and sense of impending doom. • Bronchospasm in asthmatics.

  27. Digoxin • 3 basic actions: • Positive inotrope = Increases force, strength, and velocity of contractions • Negative chronotrope = Slows heart rate, improving coronary blood flow and myocardial perfusion • Negative dromotrope = Slows conduction velocity through AV node

  28. Digoxin • Inhibits Na+K+ATPase pump  gain of intracellular Na+ • Extra Na+ removed via Na+Ca2+ exchange channel • Increased intracellular Ca2+ improves myocyte contractility • Onset: 5-30 min IV; 30-120 min PO

  29. Digoxin • Indications: • Improve cardiac output in CHF • Control ventricular response in atrial fib/flutter and PSVT

  30. Digoxin • Dosing: • 10-15 μg/kg or 0.75-1.5 mg IV • 0.125-0.5 mg/day PO • Adverse effects: • GI: abdominal pain, N/V, diarrhea • Cardiac: sinus bradycardia, AV or SA nodal block, ventricular dysrhythmias

  31. Digoxin • Toxicity: • Can be fatal if not properly treated • Symptoms are varied and can be vague • Altered mentation, visual disturbances, seizures • PVCs, VT, junctional tachycardia, high-degree AV block, SVT, and sinus arrest • Hyperkalemia

  32. Digoxin • Toxicity Treatment: • Lidocaine, phenytoin and/or atropine • Digibind (antibody fragments) IF: • Tachydysrhythmias • Sinus bradycardia • Severe AV blocks • K+ >5mEq/L secondary to digoxin use

  33. Atropine • Antagonizes acetylcholine & muscarinic agents • Increases sinus node automaticity and AV conduction by blocking vagal activity (parasympatholytic) • Onset: 2-4 minutes • Indications: • Symptomatic sinus bradycardia • PEA and asystole

  34. Atropine • Dosing: • For bradycardia = 0.5mg IVP q 3-5min • For PEA/asystole = 1mg IVP q 3-5min • Maximum total dose of 0.04 mg/kg produces complete vagal blockade

  35. Atropine • Adverse effects: • Dry mouth, CNS stimulation, hallucinations, blurred vision, and tachycardia • Potential ischemia and ventricular tachydysrhythmia in hemodynamically stable bradycardic patients

  36. Dobutamine (Dobutrex) • Sympathomimetic - inotropic and chronotropic effects • β1/ β2-adrenergic and α-adrenergic offset by α-adrenergic antagonist activity  increase in myocardial contractility and systemic vasodilation

  37. Dobutamine • Onset: 1-2 min • Indications: • Positive inotropic support for cardiovascular decompensation secondary to ventricular dysfunction or low-output heart failure. • Preferred agent to manage cardiogenic shock.  increases CO and renal/mesenteric blood flow w/o direct stimulation of the heart rate.

  38. Dobutamine • Dosing: • 2-20 μg/kg/min • Monitor patient with CVP or pulmonary artery catheter. • Adverse effects: • Increases in heart rate, blood pressure, and ectopic dysrhythmias

  39. Nitroglycerin • Enters vascular smooth muscle • Converts to nitric oxide • direct vasodilator • produces systemic venodilatation • Venodilation at <100 μg/min • Arteriolar vasodilation >200 μg/min

  40. Nitroglycerin • Indications: • Angina pectoris • Acute decompensated CHF • Hypertensive crisis • Perioperative hypertension in CV procedures • Dosing: • SL, lingually, intrabuccaly, topically or IV • Multiple formulations with specific dosing regimens

  41. Nitroglycerin • Adverse effects: • Headache, dizziness, hypotension, syncope • Remove transdermal patches and ointments before defibrillation or cardioversion • Concurrent use of sildenafil (Viagra) has been reported to cause excessive refractory hypotension

  42. Vasopressin (Pitressin) • Directly stimulates smooth muscle V1 receptors • vasoconstriction • Decreased splanchnic, coronary, GI, skin, and muscular system blood flow • May be beneficial during resuscitation attempts

  43. Vasopressin • Onset = immediate • Indications: • Alternative to epinephrine as nonadrenergic peripheral vasoconstrictor during CPR • Pulseless VT/VF

  44. Vasopressin • Dosing: • Cardiac arrest: 40 units IV push single dose • Epinephrine 1 mg IV should be given after 10 minutes if adequate response is not seen. • Adverse effects: • HTN, bradycardia, dysrhythmias, PACs, heart block, peripheral vascular constriction, and decreased cardiac output

  45. Questions • 1. Which of the following is indicated for symptomatic sinus bradycardia? • A. Labetalol • B. Atropine • C. Neseritide • D. Vasopressin • E. Digoxin • 2. Nitroglycerin may not be given: • A. Sublingually • B. Topically with cardioversion • C. Via IV infusion • D. With concomitant Viagra use • E. B & D

  46. 3. True or False? • Amiodarone is a good treatment choice for wide-complex tachydysrhythmias in patients with unknown underlying EF. • 4. Which of the following is false regarding adenosine? • A. Is indicated for emergency treatment of SVT. • B. Has a half-life of about 10 seconds. • C. Blocks anterograde conduction over accessory pathways. • D. Produces transient AV nodal block. • E. A sense of impending doom is a common side effect. • 5. What is the appropriate dose of vasopressin for pulseless VT/VF? • A. 40 units IV push • B. 1 mg IV • C. 1mg/kg/min • D. 6 mg rapid IV push • E. 300 mg IV

  47. Answers • 1. B • 2. E • 3. T • 4. C • 5. A

More Related